source
- Argenx’s FB102 meets primary endpoint in phase 2 celiac trial, paving way for pivotal studyArgenx reported that its experimental antibody FB102 achieved a statistically significant improvement in villus height‑to‑crypt depth (Vh:Cd) compared with placebo in a phase 2 study of adults with…
- Vir Biotechnology appoints David Liu as chief medical officer to steer hepatitis D phase 3 and cancer programsVir Biotechnology announced the appointment of David Liu, M.D., Ph.D., as its new chief medical officer. Liu comes from a recent stint as CMO at Nuvation Bio and has held senior roles at AstraZene…